Business Description
BioAtla Inc
NAICS : 541714
SIC : 2833
ISIN : US09077B1044
Share Class Description:
BCAB: Ordinary SharesDescription
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 41.91 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12.2 | |||||
3-Year EPS without NRI Growth Rate | 1 | |||||
3-Year FCF Growth Rate | 20.8 | |||||
3-Year Book Growth Rate | -38.2 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.06 | |||||
9-Day RSI | 42.84 | |||||
14-Day RSI | 40.06 | |||||
6-1 Month Momentum % | -35.1 | |||||
12-1 Month Momentum % | -45.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.49 | |||||
Quick Ratio | 4.49 | |||||
Cash Ratio | 4.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.6 | |||||
Shareholder Yield % | 2.24 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -120.19 | |||||
ROA % | -80.09 | |||||
ROIC % | -1639.53 | |||||
ROC (Joel Greenblatt) % | -3426.77 | |||||
ROCE % | -104.12 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.38 | |||||
Price-to-Tangible-Book | 1.39 | |||||
EV-to-EBIT | 0.08 | |||||
EV-to-Forward-EBIT | -0.01 | |||||
EV-to-EBITDA | 0.08 | |||||
EV-to-Forward-EBITDA | -0.02 | |||||
EV-to-FCF | 0.09 | |||||
Price-to-Net-Current-Asset-Value | 1.46 | |||||
Price-to-Net-Cash | 1.66 | |||||
Earnings Yield (Greenblatt) % | 1250 | |||||
FCF Yield % | -163.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioAtla Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -2.49 | ||
Beta | 1.11 | ||
Volatility % | 96.93 | ||
14-Day RSI | 40.06 | ||
14-Day ATR ($) | 0.190616 | ||
20-Day SMA ($) | 1.51425 | ||
12-1 Month Momentum % | -45.92 | ||
52-Week Range ($) | 1.24 - 4.02 | ||
Shares Outstanding (Mil) | 48.12 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioAtla Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioAtla Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
BioAtla Inc Frequently Asked Questions
What is BioAtla Inc(BCAB)'s stock price today?
The current price of BCAB is $1.43. The 52 week high of BCAB is $4.02 and 52 week low is $1.24.
When is next earnings date of BioAtla Inc(BCAB)?
The next earnings date of BioAtla Inc(BCAB) is 2024-08-01 Est..
Does BioAtla Inc(BCAB) pay dividends? If so, how much?
BioAtla Inc(BCAB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |